Pathnostics

Executive Summary

Pathnostics is a precision diagnostics company based in Irvine, CA, focused on infectious disease and cancer testing. Its flagship platform, Guidance®, addresses the significant clinical challenge of urinary tract infections (UTIs) by using Pooled Antibiotic Susceptibility Testing (P-AST™), which provides clinicians with a comprehensive antibiotic susceptibility profile from a single mixed-sample assay. This approach aims to overcome limitations of standard urine culture, which often yields inconclusive results in mixed infections. Pathnostics' technology has the potential to improve treatment outcomes and reduce antimicrobial resistance by enabling more targeted antibiotic selection. The company operates in a large, underserved market: over 8 million UTI-related physician visits occur annually in the US, and current diagnostic methods fail to identify pathogens in up to 50% of cases. Pathnostics' laboratory-developed test (LDT) is already available through its CLIA-certified lab, but broader adoption will likely require FDA clearance and integration into clinical guidelines. The company faces competition from established urine culture and emerging molecular diagnostics, but its unique P-AST method could differentiate it. With no disclosed funding rounds or revenue, the company appears early-stage, and its success hinges on regulatory milestones and commercial partnerships.

Upcoming Catalysts (preview)

• H2 2026FDA 510(k) Clearance for Guidance UTI Panel70% success
• 2026Clinical Study Publication Demonstrating Improved Outcomes50% success
• 2026Strategic Partnership with National Reference Laboratory40% success